SG11202011816VA - Drug delivery methods targeting the lymphatic system - Google Patents

Drug delivery methods targeting the lymphatic system

Info

Publication number
SG11202011816VA
SG11202011816VA SG11202011816VA SG11202011816VA SG11202011816VA SG 11202011816V A SG11202011816V A SG 11202011816VA SG 11202011816V A SG11202011816V A SG 11202011816VA SG 11202011816V A SG11202011816V A SG 11202011816VA SG 11202011816V A SG11202011816V A SG 11202011816VA
Authority
SG
Singapore
Prior art keywords
drug delivery
lymphatic system
delivery methods
methods targeting
targeting
Prior art date
Application number
SG11202011816VA
Other languages
English (en)
Inventor
Russell Frederick Ross
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of SG11202011816VA publication Critical patent/SG11202011816VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023Drug applicators using microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0046Solid microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0061Methods for using microneedles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
SG11202011816VA 2018-05-31 2019-05-30 Drug delivery methods targeting the lymphatic system SG11202011816VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862678601P 2018-05-31 2018-05-31
US201862678592P 2018-05-31 2018-05-31
US201862678584P 2018-05-31 2018-05-31
PCT/US2019/034736 WO2019232265A1 (en) 2018-05-31 2019-05-30 Drug delivery methods targeting the lymphatic system

Publications (1)

Publication Number Publication Date
SG11202011816VA true SG11202011816VA (en) 2020-12-30

Family

ID=68697699

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011816VA SG11202011816VA (en) 2018-05-31 2019-05-30 Drug delivery methods targeting the lymphatic system

Country Status (10)

Country Link
US (1) US20210228853A1 (ja)
EP (1) EP3801464A4 (ja)
JP (1) JP2021525576A (ja)
KR (1) KR20210015970A (ja)
CN (1) CN112512502A (ja)
AU (1) AU2019277577A1 (ja)
CA (1) CA3101614A1 (ja)
MX (1) MX2020012789A (ja)
SG (1) SG11202011816VA (ja)
WO (1) WO2019232265A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022192594A2 (en) 2021-03-11 2022-09-15 Sorrento Therapeutics, Inc. Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
WO2022261262A1 (en) * 2021-06-09 2022-12-15 Sorrento Therapeutics, Inc. Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device
CN113368386A (zh) * 2021-06-21 2021-09-10 温州医科大学慈溪生物医药研究院 一种结合电刺激和超声的大分子药物入脑递送系统
CN113368384A (zh) * 2021-06-21 2021-09-10 温州医科大学慈溪生物医药研究院 脂质体电渗助导的大分子药物入脑的递送系统
EP4373402A2 (en) * 2021-07-23 2024-05-29 Curiva, LLC Microneedle-mediated wearable dermal patch and methods of use for collection of biological fluid
CA3228858A1 (en) * 2021-08-18 2023-02-23 Russell F. Ross Therapeutic agents targeting the lymphatic system

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091619A1 (en) * 2001-11-14 2003-05-15 Spencer Jamison R. Temporomandibular joint patch
WO2004064889A2 (en) * 2003-01-16 2004-08-05 Becton, Dickinson And Company Intradermal cellular delivery using narrow gauge micro-cannula
CA2536669A1 (en) * 2003-08-26 2005-03-17 Becton, Dickinson And Company Methods for intradermal delivery of therapeutics agents
US20080009801A1 (en) * 2004-12-02 2008-01-10 Nickel Janice H Method for dispensing material into a drug delivery device
KR101175326B1 (ko) * 2009-04-14 2012-08-20 (주)바이오제닉스 생리 활성 물질의 경피 전달을 위한 마이크로 니들 장치 및 그 제조 방법
WO2015119906A1 (en) * 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
EP4151231A1 (en) * 2015-02-13 2023-03-22 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
EP3925599A1 (en) * 2015-07-24 2021-12-22 Sorrento Therapeutics, Inc. Methods for better delivery of active agents to tumors
KR102413032B1 (ko) * 2016-03-01 2022-06-24 노쓰 캐롤라이나 스테이트 유니버시티 마이크로니들 패치-보조된 전달에 의한 향상된 암 면역요법
EP3442542A4 (en) * 2016-03-15 2020-01-15 North Carolina State University NANOPARTICLE, DOSAGE FORM WITH CONTROLLED RELEASE, AND METHOD FOR RELEASING AN IMMUNOTHERAPEUTIC

Also Published As

Publication number Publication date
US20210228853A1 (en) 2021-07-29
WO2019232265A1 (en) 2019-12-05
KR20210015970A (ko) 2021-02-10
JP2021525576A (ja) 2021-09-27
EP3801464A4 (en) 2022-03-16
CN112512502A (zh) 2021-03-16
EP3801464A1 (en) 2021-04-14
CA3101614A1 (en) 2019-12-05
AU2019277577A1 (en) 2020-12-24
MX2020012789A (es) 2021-04-28

Similar Documents

Publication Publication Date Title
CA186677S (en) Drug delivery device
IL291415A (en) Drug delivery device
IL291155A (en) Drug delivery device
IL291004A (en) Drug delivery device
ZAA201800376S (en) Drug delivery devices
IL291295A (en) Drug delivery device
SG11202011816VA (en) Drug delivery methods targeting the lymphatic system
IL276784A (en) Drug delivery systems
EP3720522C0 (en) DRUG DELIVERY DEVICE
IL291154A (en) Drug delivery device
GB201807040D0 (en) Drug delivery
GB2576808B (en) Medicament delivery device
HUE057487T2 (hu) Gyógyszeradagoló rendszer
IL280184A (en) Drug release devices
GB201712184D0 (en) Medicament delivery device
IL274920A (en) Maytansinoid-based drug delivery systems
EP3534987A4 (en) ADJUSTABLE-DOSE DRUG DELIVERY SYSTEM
EP3720422C0 (en) LIPOSOMAL DRUG DELIVERY SYSTEM
IT201700043316A1 (it) Drug delivery system
PL3694585T3 (pl) Urządzenie do podawania leku
GB201710280D0 (en) Drug delivery apparatus
IL275664A (en) drug delivery system
IL279004A (en) Drug delivery methods targeting the lymphatic system
GB2570113B (en) Ocular drug delivery system
GB201801898D0 (en) Medicament delivery devices